Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription 20.04.2026 4 BJU Int 2 BMC Urol 2 Br J Cancer 1 Cancer 1 Cancer Imaging 2 Endocrinology 1 Eur J Radiol 2 Eur Radiol 1 Eur Urol 1 Int J Oncol 2 Int J Urol 2 J Nucl Med 1 J Urol 1 Lancet Oncol 4 Prostate 1 Radiol Imaging Cancer 4 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. UGGE H, Daouacher G, Walden M
   The 5-year outcomes of a regional population-based PSA information and testing programme.
   BJU Int. 2026;137:877-885.
   PubMed         Abstract available
   
   
2. AL-KHANATY A, Chen D, Walbaum J, Hennes D, et al
   Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.
   BJU Int. 2026 Apr 14. doi: 10.1111/bju.70283.
   PubMed         Abstract available
   
   
3. XU K, Shah N, Han DY, Koya M, et al
   Outcomes and progression predictors in a New Zealand active surveillance programme for prostate cancer.
   BJU Int. 2026 Apr 15. doi: 10.1111/bju.70276.
   PubMed         Abstract available
   
   
4. MICHELETO JPC, Suzuki TA, Santos LA, Sales LP, et al
   Micro-ultrasonography- vs MRI-targeted biopsy in prostate cancer: Updated systematic review and meta-analysis.
   BJU Int. 2026 Apr 16. doi: 10.1111/bju.70270.
   PubMed         Abstract available
   
   

   
   BMC Urol

5. CHIKAZAWA I, Kunii K, Kondou T, Miyazawa K, et al
   Anatomical approach in magnetic resonance imaging and ultrasonography fusion biopsy for prostate cancer detection: a cross-sectional study.
   BMC Urol. 2026 Apr 14. doi: 10.1186/s12894-026-02135.
   PubMed        
   
   
6. ARNOLD J
   Comprehensive comparison of Bioprotect balloon and Barrigel hydrogel rectal spacers in proton therapy for prostate cancer.
   BMC Urol. 2026 Apr 11. doi: 10.1186/s12894-026-02139.
   PubMed         Abstract available
   
   

   
   Br J Cancer

7. MAHARAJ MSN, Mertens-Walker I, Lisle JE, Herington A, et al
   SUMOylation of EphB4 enhances its stability in prostate cancer.
   Br J Cancer. 2026 Apr 15. doi: 10.1038/s41416-026-03442.
   PubMed         Abstract available
   
   
8. KONDRUP K, Iisager L, Salachan PV, Norgaard M, et al
   Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer.
   Br J Cancer. 2026 Apr 10. doi: 10.1038/s41416-026-03432.
   PubMed         Abstract available
   
   

   
   Cancer

9. GERKE MB, Marra A, Liu Y, Bedmutha A, et al
   Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617.
   Cancer. 2026;132:e70410.
   PubMed         Abstract available
   
   

   
   Cancer Imaging

10. DO DD, Domingo MR, Conlin CC, Matthews I, et al
    Systematic effects of patient factors and scanner/protocol factors on a Restriction Spectrum Imaging (RSI) quantitative MRI biomarker for prostate cancer.
    Cancer Imaging. 2026 Apr 16. doi: 10.1186/s40644-026-01032.
    PubMed        
    
    

    
    Endocrinology

11. KOUSPOU M, Zhu A, Martires L, Tewari AK, et al
    Intersection of Phenotypic Plasticity and Anoikis Enhances Therapeutic Vulnerability in Prostate Cancer.
    Endocrinology. 2026 Apr 17:bqag046. doi: 10.1210.
    PubMed         Abstract available
    
    
12. EFFAH W, Khalil M, Sukla S, Zhao C, et al
    Role of Janus kinase-signal transducer and activator of transcription signaling pathway in hormonal cancer therapeutic resistance and lineage plasticity.
    Endocrinology. 2026;167:bqag035.
    PubMed         Abstract available
    
    

    
    Eur J Radiol

13. SONG JS, Jang W
    Prostate MRI quality assessment using PI-QUAL version 2: Comparative analysis between 1.5 T and 3 T scanners and its association with T-staging agreement.
    Eur J Radiol. 2026;199:112821.
    PubMed         Abstract available
    
    

    
    Eur Radiol

14. STEGARESCU P, Burian E, Lutz A, Perlis N, et al
    Prostate MRI learning curves: establishing training benchmarks for radiology and urology trainees.
    Eur Radiol. 2026;36:3431-3441.
    PubMed         Abstract available
    
    
15. WALLSTROM J, Jaderling F, Langkilde F, Arnsrud Godtman R, et al
    Ongoing and completed clinical trials on prostate cancer screening using MRI.
    Eur Radiol. 2026 Apr 16. doi: 10.1007/s00330-026-12533.
    PubMed         Abstract available
    
    

    
    Eur Urol

16. GARNICK MB, Herrmann K
    Considerations for Earlier Use of Radiopharmaceutical Therapy in Prostate Cancer.
    Eur Urol. 2026 Apr 15:S0302-2838(26)02036-1. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    

    
    Int J Oncol

17. WANG Y, Xie Y, Zhao Q
    Novel therapeutic strategies for metastatic castration?resistant prostate cancer: Beyond androgen receptor pathway inhibition (Review).
    Int J Oncol. 2026;68:69.
    PubMed         Abstract available
    
    

    
    Int J Urol

18. HARA T, Matsumoto K, Nirazuka A, Kanehira M, et al
    Nationwide Real-World Outcomes of Robot-Assisted Radical Prostatectomy Using the Hinotori Surgical Robot System in Japan.
    Int J Urol. 2026;33:e70460.
    PubMed         Abstract available
    
    
19. AKAGI N, Nagoshi A, Kubota M, Hagimoto H, et al
    Hemorrhagic Risk of Transrectal Ultrasound-Guided Prostate Biopsy Under Continued Antithrombotic Therapy.
    Int J Urol. 2026;33:e70462.
    PubMed         Abstract available
    
    

    
    J Nucl Med

20. UNTERRAINER LM, Ndlovu H, Hope TA, Unterrainer M, et al
    Prognostic Value of PSMA PET-Derived Tumor Burden Stratification in Metastatic Hormone-Sensitive Prostate Cancer.
    J Nucl Med. 2026 Apr 16:jnumed.125.271598. doi: 10.2967/jnumed.125.271598.
    PubMed         Abstract available
    
    
21. SHIOTA M, Fujiwara M, Sumiyoshi T, Enokida H, et al
    Circulating Tumor DNA Genomic Profiling in (223)Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 Study.
    J Nucl Med. 2026 Apr 16:jnumed.126.272073. doi: 10.2967/jnumed.126.272073.
    PubMed         Abstract available
    
    

    
    J Urol

22. EASTHAM JA, Barocas DA, Chu CE, Morgans AK, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026).
    J Urol. 2026 Apr 16:101097JU0000000000005060. doi: 10.1097/JU.0000000000005060.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

23. MORGANS AK, Haresh KP, Jievaltas M, Olmos D, et al
    Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2026 Apr 9:S1470-2045(26)00014.
    PubMed         Abstract available
    
    

    
    Prostate

24. BALAJI S, Mottaghi M, Koffer PP, Polascik TJ, et al
    Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer.
    Prostate. 2026 Apr 15. doi: 10.1002/pros.70181.
    PubMed         Abstract available
    
    
25. EKER A, Diler F, Tatar SY, Hasbay E, et al
    In the Era of mpMRI and PSMA PET/CT: Does Digital Rectal Examination Still Matter?
    Prostate. 2026;86:805-810.
    PubMed         Abstract available
    
    
26. ABDSHAH A, Alyamani M, Burgess RA, Parekh DJ, et al
    Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker Investigation.
    Prostate. 2026;86:771-783.
    PubMed         Abstract available
    
    
27. SHIMOMURA T, Murakami M, Kasai K, Imai Y, et al
    Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features.
    Prostate. 2026 Apr 17. doi: 10.1002/pros.70183.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

28. TWILT JJ, Saha A, Bosma JS, Giannarini G, et al
    Evaluating an AI-driven Triaging Workflow for MRI-based Clinically Significant Prostate Cancer Diagnosis: A Simulation Study.
    Radiol Imaging Cancer. 2026;8:e250461.
    PubMed         Abstract available
    
    

    
    Urology

29. MANIVASAGAM SS
    Editorial Comment on "Primary Care Physician Led Population Based Screening Program for Prostate Cancer: Bridging a Urologic Gap in Access to Care".
    Urology. 2026 Apr 14:S0090-4295(26)00247-5. doi: 10.1016/j.urology.2026.
    PubMed        
    
    
30. MEHR JP, Talwar R
    Editorial Comment on "Patient preferences for treatment of intermediate-risk prostate cancer: A discrete choice experiment".
    Urology. 2026 Apr 14:S0090-4295(26)00248-7. doi: 10.1016/j.urology.2026.
    PubMed        
    
    
31. NAELITZ BD, Siva J, Vallabhaneni S, Momtazi-Mar L, et al
    Varicocele and Untreated Hypogonadism Synergistically Increase Prostate Cancer Risk via Testosterone Shunt Physiology and can be Ameliorated with Testosterone Therapy.
    Urology. 2026 Apr 14:S0090-4295(26)00243-8. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    
32. FINK KE, Liu Y, Wiarda G, Gowda A, et al
    Comparative Performance of Prostate Cancer Risk Prediction Tools in Gay, Bisexual, and Other Men Who Have Sex with Men Versus Heterosexual Men.
    Urology. 2026 Apr 13:S0090-4295(26)00236-0. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum